Cargando…

Development and validation of an equation to predict the incidence of coronary heart disease in patients with type 2 diabetes in Japan

OBJECTIVE: In the diabetes treatment policy after the Kumamoto Declaration 2013, it is difficult to accurately predict the incidence of complications in patients using the JJ risk engine. This study was conducted to develop a prediction equation suitable for the current diabetes treatment policy usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Yasunari, Inoue, Gaku, Nozaki, Yoichi, Kitajima, Rina, Matsubara, Kiyoshi, Horii, Takeshi, Mohri, Junichi, Atsuda, Koichiro, Matsubara, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613942/
https://www.ncbi.nlm.nih.gov/pubmed/34823578
http://dx.doi.org/10.1186/s13104-021-05844-w
Descripción
Sumario:OBJECTIVE: In the diabetes treatment policy after the Kumamoto Declaration 2013, it is difficult to accurately predict the incidence of complications in patients using the JJ risk engine. This study was conducted to develop a prediction equation suitable for the current diabetes treatment policy using patient data from Kitasato University Kitasato Institute Hospital (Hospital A) and to externally validate the developed equation using patient data from Kitasato University Hospital (Hospital B). Outlier tests were performed on the patient data from Hospital A to exclude the outliers. Prediction equation was developed using the patient data excluding the outliers and was subjected to external validation. RESULTS: By excluding outlier data, we could develop a new prediction equation for the incidence of coronary heart disease (CHD) as a complication of type 2 diabetes, incorporating the use of antidiabetic drugs with a high risk of hypoglycemia. This is the first prediction equation in Japan that incorporates the use of antidiabetic drugs. We believe that it will be useful in preventive medicine for treatment for people at high risk of CHD as a complication of diabetes or other diseases. In the future, we would like to confirm the accuracy of this equation at other facilities. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-021-05844-w.